Uncategorized

Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win

Published

2 hours ago

on

Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version